BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl. 2010;4:892-903. [PMID: 21137030 DOI: 10.1002/prca.201000073] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ioannidis JPA, Bossuyt PMM. Waste, Leaks, and Failures in the Biomarker Pipeline. Clinical Chemistry 2017;63:963-72. [DOI: 10.1373/clinchem.2016.254649] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 20.0] [Reference Citation Analysis]
2 Clerico A, Zaninotto M, Padoan A, Masotti S, Musetti V, Prontera C, Ndreu R, Zucchelli G, Passino C, Migliardi M, Plebani M. Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Elsevier; 2019. pp. 239-62. [DOI: 10.1016/bs.acc.2019.07.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
3 Xiang D, Zhang H, Bai J, Ma J, Li M, Gao W, Zhang X, Gao J, Wang C. Particle-enhanced turbidimetric immunoassay for determination of serum neutrophil gelatinase-associated lipocalin on the Roche Cobas c501 analyzer. Clinical Biochemistry 2013;46:1756-60. [DOI: 10.1016/j.clinbiochem.2013.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Behrens T, Bonberg N, Casjens S, Pesch B, Brüning T. A practical guide to epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2014;1844:145-55. [DOI: 10.1016/j.bbapap.2013.07.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
5 Patil S, Majumdar B, Awan KH, Sarode GS, Sarode SC, Gadbail AR, Gondivkar S. Cancer oriented biobanks: A comprehensive review. Oncol Rev 2018;12:357. [PMID: 30057691 DOI: 10.4081/oncol.2018.357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 2015;61:809-20. [PMID: 25882892 DOI: 10.1373/clinchem.2015.239863] [Cited by in Crossref: 91] [Cited by in F6Publishing: 61] [Article Influence: 15.2] [Reference Citation Analysis]
7 Raths S, Parkel S, Bredmose J, Daussin V. Mind the gap! A survey of the challenges of biomarker commercialization. Drug Discovery Today 2020;25:22-6. [DOI: 10.1016/j.drudis.2019.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vidal M, Chan DW, Gerstein M, Mann M, Omenn GS, Tagle D, Sechi S; Workshop Participants. The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics 2012;9:6. [PMID: 22583803 DOI: 10.1186/1559-0275-9-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
9 Lopez-Anton M, Bowen T, Jenkins RH. microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. Biomed Res Int 2015;2015:929806. [PMID: 26495316 DOI: 10.1155/2015/929806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Gohar F, Mcardle A, Jones M, Callan N, Hernandez B, Kessel C, Miranda-garcia M, Lavric M, Holzinger D, Pretzer C, Lainka E, Vastert SJ, de Roock S, Fitzgerald O, Pennington SR, Foell D. Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 2019;78:1107-13. [DOI: 10.1136/annrheumdis-2019-215051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Aimo A, Januzzi JL Jr, Vergaro G, Ripoli A, Latini R, Masson S, Magnoli M, Anand IS, Cohn JN, Tavazzi L, Tognoni G, Gravning J, Ueland T, Nymo SH, Rocca HB, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Wilson Tang WH, Grodin JL, Passino C, Emdin M. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. Int J Cardiol 2019;277:166-72. [PMID: 30416028 DOI: 10.1016/j.ijcard.2018.10.079] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
12 Bratulic S, Gatto F, Nielsen J. The Translational Status of Cancer Liquid Biopsies. Regen Eng Transl Med . [DOI: 10.1007/s40883-019-00141-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
13 Kaur G, Poljak A, Ali SA, Zhong L, Raftery MJ, Sachdev P. Extending the Depth of Human Plasma Proteome Coverage Using Simple Fractionation Techniques. J Proteome Res 2021;20:1261-79. [PMID: 33471535 DOI: 10.1021/acs.jproteome.0c00670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Nallagangula KS, Shashidhar KN, Lakshmaiah V, Muninarayana. Evolution of proteomic biomarker for chronic liver disease: Promise into reality. J Circ Biomark 2018;7:1849454418777186. [PMID: 29854010 DOI: 10.1177/1849454418777186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, Robinson WH, Hesterberg LK. Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods 2012;378:72-80. [PMID: 22366959 DOI: 10.1016/j.jim.2012.02.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
16 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Wilson BM, Moran MM, Meagher MJ, Ross RD, Mashiatulla M, Virdi AS, Sumner DR. Early changes in serum osteocalcin and body weight are predictive of implant fixation in a rat model of implant loosening. J Orthop Res 2020;38:1216-27. [PMID: 31825107 DOI: 10.1002/jor.24563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kawahara R, Bollinger JG, Rivera C, Ribeiro AC, Brandão TB, Paes Leme AF, MacCoss MJ. A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva. Proteomics 2016;16:159-73. [PMID: 26552850 DOI: 10.1002/pmic.201500224] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
19 Sturgeon C, Selby P. Development and validation of new biomarkers: major opportunities for health-care scientists. Ann Clin Biochem 2010;47:499-502. [DOI: 10.1258/acb.2010.201020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Kift RL, Messenger MP, Wind TC, Hepburn S, Wilson M, Thompson D, Smith MW, Sturgeon C, Lewington AJ, Selby PJ, Banks RE. A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem 2013;50:236-44. [PMID: 23605129 DOI: 10.1258/acb.2012.012117] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
21 Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomed Hub 2020;5:182-223. [PMID: 33564664 DOI: 10.1159/000511209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mourino-Alvarez L, Baldan-Martin M, Rincon R, Martin-Rojas T, Corbacho-Alonso N, Sastre-Oliva T, Barderas MG. Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. Expert Rev Proteomics 2017;14:701-13. [PMID: 28689450 DOI: 10.1080/14789450.2017.1353912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) 2015;5:219-53. [PMID: 26854151 DOI: 10.3390/diagnostics5020219] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
24 Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European Journal of Cancer 2017;75:284-98. [DOI: 10.1016/j.ejca.2017.01.017] [Cited by in Crossref: 220] [Cited by in F6Publishing: 197] [Article Influence: 55.0] [Reference Citation Analysis]
25 Barderas MG, Vivanco F, Alvarez-llamas G. Vascular Proteomics. In: Vivanco F, editor. Vascular Proteomics. Totowa: Humana Press; 2013. pp. 1-20. [DOI: 10.1007/978-1-62703-405-0_1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
26 Justice AC, Erlandson KM, Hunt PW, Landay A, Miotti P, Tracy RP. Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? J Infect Dis 2018;217:521-8. [PMID: 29165684 DOI: 10.1093/infdis/jix586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
27 Murphy L, Prencipe M, Gallagher WM, Watson RW. Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert Review of Molecular Diagnostics 2015;15:491-503. [DOI: 10.1586/14737159.2015.1011622] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Faraldi M, Gomarasca M, Perego S, Sansoni V, Banfi G, Lombardi G. Effect of collection matrix, platelet depletion, and storage conditions on plasma extracellular vesicles and extracellular vesicle-associated miRNAs measurements. Clin Chem Lab Med 2021;59:893-903. [PMID: 33555147 DOI: 10.1515/cclm-2020-1296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 de la Cuesta F, Mourino-alvarez L, Baldan-martin M, Moreno-luna R, Barderas MG. Contribution of proteomics to the management of vascular disorders. Translational Proteomics 2015;7:3-14. [DOI: 10.1016/j.trprot.2014.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sturgeon CM. External quality assessment of hormone determinations. Best Practice & Research Clinical Endocrinology & Metabolism 2013;27:803-22. [DOI: 10.1016/j.beem.2013.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
31 Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem 2013;59:52-9. [PMID: 23034139 DOI: 10.1373/clinchem.2011.180778] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
32 Chahrour O, Cobice D, Malone J. Stable isotope labelling methods in mass spectrometry-based quantitative proteomics. J Pharm Biomed Anal 2015;113:2-20. [PMID: 25956803 DOI: 10.1016/j.jpba.2015.04.013] [Cited by in Crossref: 164] [Cited by in F6Publishing: 133] [Article Influence: 27.3] [Reference Citation Analysis]
33 Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res 2018;10:4333-47. [PMID: 30349367 DOI: 10.2147/CMAR.S174435] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
34 Corbacho-Alonso N, Rodríguez-Sánchez E, Martin-Rojas T, Mouriño-Alvarez L, Sastre-Oliva T, Hernandez-Fernandez G, Padial LR, Ruilope LM, Ruiz-Hurtado G, Barderas MG. Proteomic investigations into hypertension: what's new and how might it affect clinical practice? Expert Rev Proteomics 2019;16:583-91. [PMID: 31195841 DOI: 10.1080/14789450.2019.1632197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Sesler CL, Grigorenko EV. Analytical Validation of qPCR-Based Multivariate Index Assays in a Clinical Laboratory: Practical Challenges and Limitations. J Appl Lab Med 2018;3:267-81. [PMID: 33636934 DOI: 10.1373/jalm.2017.025924] [Reference Citation Analysis]
36 Ismail OZ, Bhayana V, Kadour M, Lepage N, Gowrishankar M, Filler G. Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada. Clinical Biochemistry 2017;50:380-4. [DOI: 10.1016/j.clinbiochem.2017.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol 2013;10:206-18. [PMID: 23443013 DOI: 10.1038/nrurol.2013.24] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
38 Brenner DJ. Exploring two two-edged swords. Radiat Res 2012;178:7-16. [PMID: 22738761 DOI: 10.1667/rr3085.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
39 Navratilova Z, Kolek V, Petrek M. Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease. Arch Immunol Ther Exp 2016;64:177-93. [DOI: 10.1007/s00005-015-0375-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
40 Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Gohar F, Kessel C, Lavric M, Holzinger D, Foell D. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther 2016;18:163. [PMID: 27411444 DOI: 10.1186/s13075-016-1069-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
42 Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13. [PMID: 24088261 DOI: 10.1186/1559-0275-10-13] [Cited by in Crossref: 244] [Cited by in F6Publishing: 201] [Article Influence: 30.5] [Reference Citation Analysis]
43 Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem 2013;59:1447-56. [PMID: 23656699 DOI: 10.1373/clinchem.2012.200477] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
44 Gupta V, Davancaze T, Good J, Kalia N, Anderson M, Wallin JJ, Brady A, Song A, Xu W. Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex platform. Bioanalysis 2016;8:2415-28. [DOI: 10.4155/bio-2016-0196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Yu JP, Xu XG, Ma RJ, Qin SN, Wang CR, Wang XB, Li M, Li MS, Ma Q, Xu WW. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. J Clin Lab Anal 2015;29:85-93. [PMID: 24687454 DOI: 10.1002/jcla.21733] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
46 Torsetnes SB, Nordlund MS, Paus E, Halvorsen TG, Reubsaet L. Digging deeper into the field of the small cell lung cancer tumor marker ProGRP: a method for differentiation of its isoforms. J Proteome Res 2013;12:412-20. [PMID: 23190087 DOI: 10.1021/pr300751j] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]